Synced daily from ClinicalTrials.gov via AACT. Last sync: .
18 Inebilizumab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 15 indications (including Neuromyelitis Optica Spectrum Disorder & Neuromyelitis Optica Spectrum Disorders) and 2,175 total planned enrollment. 5 Phase 3 Inebilizumab trials and 6 Phase 2, 3 Phase 4 are listed. 10 Inebilizumab clinical trials are actively recruiting at 54 U.S. sites across 23 states. Most recent activity: NCT07598825 (Feb 2034).
Where to Participate: All Inebilizumab Trial Sites in the U.S. (54 sites across 23 states)
Every actively recruiting Inebilizumabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
THYMEA Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
Safety and Tolerability of Inebilizumab, VIB4920, or the Combination in Highly Sensitized Candidates Awaiting Kidney Transplantation From a Deceased Donor
Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders (1)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
NCT04174677withdrawnSafety and Tolerability of Inebilizumab, VIB4920, or the Combination in Highly Sensitized Candidates Awaiting Kidney Transplantation From a Deceased Donor
All Inebilizumab trials (18)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
Safety and Tolerability of Inebilizumab, VIB4920, or the Combination in Highly Sensitized Candidates Awaiting Kidney Transplantation From a Deceased Donor
18 Inebilizumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 5 are actively recruiting participants. 1 is marked completed.
Are Inebilizumab clinical trials recruiting in 2026?
Yes — 5 Inebilizumab trials are actively recruiting in 2026, with 54 U.S. sites across 23 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Inebilizumab being studied for?
Inebilizumab is being studied for Neuromyelitis Optica Spectrum Disorder, Neuromyelitis Optica Spectrum Disorders, Autoimmune Diseases, Autoimmune Encephalitis, Autoimmune Hepatitis and 16 more. The trials are grouped by indication on this page.
What phase is Inebilizumab in?
Inebilizumab clinical trials span 3 Phase 4, 5 Phase 3, 6 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Inebilizumab clinical trials?
The lead sponsor across the most Inebilizumab trials is Amgen, with 9 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Inebilizumabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.